Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease
Renal cell carcinoma represents the most common malignancy of the kidney and the majority of cases are categorized as clear cell carcinomas. The elucidation of the specific alterations in key molecular and metabolic pathways responsible for cancer development and progression have prompted the ration...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://oncologyreviews.org/site/article/view/530 |
| _version_ | 1797966020856512512 |
|---|---|
| author | Stavros Gkolfinopoulos Amanda Psyrri Aristotelis Bamias |
| author_facet | Stavros Gkolfinopoulos Amanda Psyrri Aristotelis Bamias |
| author_sort | Stavros Gkolfinopoulos |
| collection | DOAJ |
| description | Renal cell carcinoma represents the most common malignancy of the kidney and the majority of cases are categorized as clear cell carcinomas. The elucidation of the specific alterations in key molecular and metabolic pathways responsible for cancer development and progression have prompted the rationalization of our classification of this disease and have provided specific targetable molecules implicated in carcinogenesis. Although immunotherapy has been an established option in the treatment of metastatic renal cell cancer for many years, its role has been renewed and upgraded with the implementation of anti-angiogenic agents and immune checkpoint inhibitors in our treatment armamentarium. The future holds promise, as newer agents become available and combination regimens of immunotherapy with anti-angiogenic agents have become the standard of care in the management of metastatic disease and are currently being evaluated in earlier settings. Proper patient selection and individualization of our treatment strategies are of utmost importance in order to provide optimal care to patients suffering from renal cell carcinoma. |
| first_indexed | 2024-04-11T02:09:14Z |
| format | Article |
| id | doaj.art-1fb7aef36c8042389d43dd92cf26a6fa |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T02:09:14Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-1fb7aef36c8042389d43dd92cf26a6fa2023-01-03T02:26:08ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652021-02-0115110.4081/oncol.2021.530Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic diseaseStavros Gkolfinopoulos0Amanda Psyrri1Aristotelis Bamias22nd Propaedeutic Dept. of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, Athens2nd Propaedeutic Dept. of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, Athens2nd Propaedeutic Dept. of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, AthensRenal cell carcinoma represents the most common malignancy of the kidney and the majority of cases are categorized as clear cell carcinomas. The elucidation of the specific alterations in key molecular and metabolic pathways responsible for cancer development and progression have prompted the rationalization of our classification of this disease and have provided specific targetable molecules implicated in carcinogenesis. Although immunotherapy has been an established option in the treatment of metastatic renal cell cancer for many years, its role has been renewed and upgraded with the implementation of anti-angiogenic agents and immune checkpoint inhibitors in our treatment armamentarium. The future holds promise, as newer agents become available and combination regimens of immunotherapy with anti-angiogenic agents have become the standard of care in the management of metastatic disease and are currently being evaluated in earlier settings. Proper patient selection and individualization of our treatment strategies are of utmost importance in order to provide optimal care to patients suffering from renal cell carcinoma.https://oncologyreviews.org/site/article/view/530Renal cell carcinomaclear cellVEGFmTORVHL. |
| spellingShingle | Stavros Gkolfinopoulos Amanda Psyrri Aristotelis Bamias Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease Oncology Reviews Renal cell carcinoma clear cell VEGF mTOR VHL. |
| title | Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease |
| title_full | Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease |
| title_fullStr | Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease |
| title_full_unstemmed | Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease |
| title_short | Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease |
| title_sort | clear cell renal cell carcinoma a comprehensive review of agents used in the contemporary management of advanced metastatic disease |
| topic | Renal cell carcinoma clear cell VEGF mTOR VHL. |
| url | https://oncologyreviews.org/site/article/view/530 |
| work_keys_str_mv | AT stavrosgkolfinopoulos clearcellrenalcellcarcinomaacomprehensivereviewofagentsusedinthecontemporarymanagementofadvancedmetastaticdisease AT amandapsyrri clearcellrenalcellcarcinomaacomprehensivereviewofagentsusedinthecontemporarymanagementofadvancedmetastaticdisease AT aristotelisbamias clearcellrenalcellcarcinomaacomprehensivereviewofagentsusedinthecontemporarymanagementofadvancedmetastaticdisease |